ArticleAntimicrobial resistance and infection control2025
Asymptomatic faecal carriage of vancomycin-resistant Enterococci among inpatients and outpatients in a Kenyan hospital: a cross-sectional study.
Article in Antimicrobial resistance and infection control, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVancomycin-resistant Enterococci (VRE) strains are a growing public health concern globally; however, epidemiological data to inform infection prevention and control interventions in line with antimicrobial resistance (AMR) global and national action plans in our study setting are limited. Here, we assessed VRE asymptomatic faecal carriage, AMR profiles and risk factors among inpatients and outpatients in a county referral hospital in Kenya.
methodsThis was a cross-sectional study design among adult patients (≥ 18) at the Kiambu County Referral Hospital outpatient department (OPD) and patients in the inpatient department (IPD) from June to September 2022. A systematic random sampling technique was employed to recruit 155 participants from the OPD, excluding patients presenting with histories of diarrhoea, antibiotics use (≤ 48 h), and ≤ 90 days previous admission. In IPD, 155 patients admitted for ≥ 48 h, were consecutively enrolled, excluding diarrhoea cases. The participants' sociodemographic and clinical data were collected using a structured questionnaire, with stool samples collected in sterile containers and transported in an icebox to Kenya Medical Research Institute, Nairobi, for analysis within 4-6 h, using standard and automated bacteriological methods.
resultsThe overall faecal carriage of VRE was 5.2%, 95% confidence interval (CI): 2.98-8.25% (16/310), highest among the outpatients (3.9%; 12/310), 95% CI: 2.02-6.66%) where Enterococcus faecium predominated (overall: 62.5%, 10/16; IPD: 18.8%, 3/16; OPD: 43.8%, 7/16). VRE isolates were 100% resistant to erythromycin and tetracycline, with 31.3% (5/16) non-susceptible to teicoplanin, but remained sensitive to linezolid, tigecycline, and nitrofurantoin. Sixty-three per cent (62.5%, 10/16) of VRE isolates were multidrug-resistant, predominated by E. faecium (80%, 8/10). The multiple antibiotic resistance index (MARI) was > 0.2. The independent predictors of VRE carriage were female gender (aOR = 10.8, 95% CI 1.1-110.1, p = 0.045) and antibiotic dose completion behaviour (aOR = 0.122, 95% CI 0.0002-1.0, p = 0.046) among the outpatients.
conclusionWe report asymptomatic faecal carriage of VRE strains that are MDR predominately among outpatients, whereby females and patients with a history of not completing an antibiotic prescription were at increased risk of colonization. To inform infection prevention interventions, establishing the transmission mechanisms and sustained AMR surveillance are warranted to mitigate VRE spread in our study area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.